In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories

Brexit To And Fro Continues Into Fresh Decade

Three Brexit deadlines have come and gone, and the UK is still a member of the European Union. It will remain so until it agrees a withdrawal deal or leaves without one at the end of January 2020. Alternatively, it could secure yet another extension to the Article 50 period beyond January 31. Or it could decide not to leave at all.

Business Strategies Policy

The Drug Hunter’s Assistant: Accelerating Drug Discovery With AI

The hype around Artificial Intelligence has been deafening in recent years, but real progress can only come when drug discovery culture and regulators catch up with the technology.

Digital Health Research and Development Strategies Artificial Intelligence

Denmark Offers One-Stop-Shop For Clinical Trials

Denmark’s Trial Nation Portal was established in 2018 with government backing and the aim of luring clinical trials to the country. 

Denmark Sweden Research and Development Strategies

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development

Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More

Recent Issues

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Taking Aim At Advanced Therapies

Dmitry Kuzmin, managing partner, and Owen Smith, investment director, talk to In Vivo about 4BIO’s approach to venture investing in the biopharma sector: successes, red flags and targets for its second fund.

VC Playbook Business Strategies

PureTech’s Problem-Solving Skills Target The BIG Picture

PureTech Health has amassed niche expertise and built a unique structure that allows it to develop technologies for unmet needs, in the separate but related areas of brain-immune-gut. And now, with the experienced ex-Sanofi CEO Chris Viehbacher as interim chair, PureTech can target a smooth path to its next growth stages in the “BIG Axis.” Senior executives Eric Elenko and Joep Muijrers reveal more about the focus and aims of the Boston, US group.

C-Suite Speaks Business Strategies

MorphoSys: A European Champion Crossing The Biopharma Rubicon

The Munich-based company is one of a handful of mature European biotechs poised to enter the big league. New CEO Jean-Paul Kress talks to In Vivo about the firm’s next generation antibody platform and why US expansion is crucial to its future.

BioPharmaceutical C-Suite Speaks

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

C-Suite Snippets: Behind The Scenes At Gates Medical Research Institute

In case you missed it: catch up with snippets from interviews recently published by In Vivo.

C-Suite Speaks Market Access

Global Health Systems Are Learning To Embrace AI As A Force For Good

The term artificial intelligence was coined at the Dartmouth Summer Research Project in 1956, but it is only in very recent years that it has been consistently at the top of the agenda in discussions on the future direction of health care. As a tool to improve both the quality and speed of care, AI is now increasingly seen as a realistic solution to the demand overload on clinicians. At the same time, techno-fears are abating. This confluence will transform health care radically in the next two decades.

Outlook 2020 Artificial Intelligence

Accessing CAR-T Therapies

Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.

Innovation Pricing Strategies

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Execs On The Move, November 2019

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

Gates Foundation Plots A Fresh Metric For Market Access: Lives Saved

In Vivo visits Gates Medical Research Institute CEO Dr. Penny Heaton to review its first pipeline of drugs and vaccines to attack four of the world’s biggest killers: TB, malaria, enteric diseases and other conditions affecting maternal, newborn and child health.

C-Suite Speaks Leadership

Welcome To Alexion 2.0

In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.

C-Suite Speaks Outlook 2020

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

C-Suite Snippets: Behind The Scenes At Gates Medical Research Institute

In case you missed it: catch up with snippets from interviews recently published by In Vivo.

C-Suite Speaks Market Access

Gates MRI CEO Penny Heaton Speaks …

Insights from Gates Medical Research Institute CEO Dr. Penny Heaton. 

C-Suite Speaks Market Access

We Need To Talk – When To Get Early Scientific Advice

Hearing direct from HTA agencies on what evidence they want to see is now an option through early dialogue. With many options for early dialogue available, it is hard for companies to know whether to get advice, from which agency and how to get the most out of the dialogue.

BioPharmaceutical Europe

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

US Generics Market Continues To Seek Stability

As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.

BioPharmaceutical Market Intelligence

Brexit To And Fro Continues Into Fresh Decade

Three Brexit deadlines have come and gone, and the UK is still a member of the European Union. It will remain so until it agrees a withdrawal deal or leaves without one at the end of January 2020. Alternatively, it could secure yet another extension to the Article 50 period beyond January 31. Or it could decide not to leave at all.

Business Strategies Policy

Big Pharma’s Aging Antibodies Cling To Their Crowns

The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?

BioPharmaceutical Commercial
UsernamePublicRestriction

Register